It has been known for some time that some of the anticancer effects of chemotherapy originate from an immune-based response. Now, researchers have uncovered this mechanism in more detail in a mouse study published in Nature Medicine. The investigators showed that anthracyclines can cause a rapid production of type I interferon by tumour cells that is caused by activation of the Toll-like receptor 3 (Tlr3). The type I interferon molecules are able to trigger autocrine and paracrine signalling loops that release CXC chemokine ligand 10 (CXCL10). Tumours in mice that lacked Tlr3 failed respond to chemotherapy unless type I interferon or CXCL10 was present. Moreover, in several independent patient cohorts who had breast cancer associated with a poor prognosis, a type I interferon-like molecular signature was able to predict clinical response to treatment with chemotherapy.
References
Sistigu, A. et al. Cancer cell–autonomous contribution of type I interferon signalling to the efficacy of chemotherapy. Nat. Med. 10.1038/nm.3708
Rights and permissions
About this article
Cite this article
Interferon's helping hand with chemotherapy efficacy. Nat Rev Clin Oncol 11, 682 (2014). https://doi.org/10.1038/nrclinonc.2014.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.196